Scarica l'app Stockscreener
0.4475
1.64%
0.0072
Dopo l'orario di chiusura:
.45
0.0025
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCLX Giù?
Forum
Previsione
Precedente Chiudi:
$0.4403
Aprire:
$0.442
Volume 24 ore:
977.32K
Relative Volume:
0.47
Capitalizzazione di mercato:
$71.72M
Reddito:
$46.74M
Utile/perdita netta:
$-114.33M
Rapporto P/E:
-0.7443
EPS:
-0.6012
Flusso di cassa netto:
$-21.04M
1 W Prestazione:
-11.82%
1M Prestazione:
-20.74%
6M Prestazione:
-77.17%
1 anno Prestazione:
-65.58%
Intervallo 1D:
$0.43
$0.45
Intervallo di 1 settimana:
$0.43
$0.5399
Portata 52W:
$0.43
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Nome
Scilex Holding Company
Settore
Industria
Telefono
(650) 516-4310
Indirizzo
960 SAN ANTONIO ROAD, PALO ALTO
Confronta SCLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
0.4475 | 71.72M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Alliance Global Partners | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-16 | Iniziato | B. Riley Securities | Buy |
| 2023-10-13 | Iniziato | B. Riley Securities | Buy |
| 2023-10-09 | Iniziato | H.C. Wainwright | Buy |
Scilex Holding Company Borsa (SCLX) Ultime notizie
Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa
Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks
Palo Alto pharmaceutical company secures $17M - Silicon Valley Business Journal
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Scilex Holding Company closes registered direct offering - Medical Buyer
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times
Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks
Scilex secures $17 million in stock and warrant sale - Investing.com
Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times
Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks
Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times
SCLX: Deal Brings Huge Potential - Research Tree
Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria
Scilex Holding agrees to share sale to meet debt obligations - Investing.com
Scilex Announces Joint Venture for CNS Compound Development - TipRanks
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times
NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire
NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - The Manila Times
Scilex and IPMC announce joint venture for obesity drug By Investing.com - Investing.com UK
Scilex Holding Company Enters into a Binding Term Sheet for - GlobeNewswire
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat
Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa
Scilex receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Scilex Holding Co reaches agreement to waive default penalties - Investing.com
Scilex receives Nasdaq non-compliance notice - Investing.com India
Scilex Holding Company Announces Receipt of Notice from Nasdaq - The Manila Times
Scilex Holding Company Announces Receipt of Notice from Nasdaq - GlobeNewswire Inc.
Sciatica Market Report 2032, DelveInsight | Sciatica Therapies & Companies, Clinical trials, Sciatica Treatment | Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kol - The Globe and Mail
Open Text Corp (OTEX-Q) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 1419, 2024 - The Manila Times
Scilex Holding Company Announces Presentation of Data at - GlobeNewswire
Scilex Holding Company Announces Presentation of Data at the 2024 American College of ... - The Bakersfield Californian
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 - Yahoo Finance
Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - Simply Wall St
SCLX stock touches 52-week low at $0.73 amid market challenges - Investing.com
Denali Capital (DECA) Secures Extension for Merger Deal, Issues $180K Note to Scilex - StockTitan
Scilex shares face delisting risk on Nasdaq - Investing.com India
Scilex Holding Plans Merger to Boost Semnur Value - TipRanks
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Pre - The Manila Times
Scilex Holding Company Azioni (SCLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Scilex Holding Company Azioni (SCLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
| Followwill Dorman | Director |
Jun 26 '24 |
Option Exercise |
1.37 |
1,000 |
1,370 |
1,300 |
1.83%
1.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):